Affordable prescription drugs; create task force to study impact of alternative funding programs on patient access to.

HB 1390 creates a task force composed of the Mississippi Rare Disease Advisory Council members (or their designees) to study how alternative funding programs affect patient access to affordable prescription drugs. The task force must complete its study by December 1, 2025, examining program types, business models, and impacts on patient assistance programs and insurance coverage. The bill died in committee on February 4, 2025, and does not enact any direct policy changes - only authorizes a study to inform future legislation.